RETRACTED: Rheumatoid arthritis (RA) and cardiovascular disease (Autoimmunity Reviews (2019) 18(7) (679–690), (S1568997219301089), (10.1016/j.autrev.2019.05.005));Rheumatoid arthritis (RA) and cardiovascular disease

Autoimmunity Reviews

Volumn 18, Issue 7, 2019, Pages 679-690

  Blum, Arnon ^a   Adawi, Mohammad ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE; RITUXIMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

ATHEROSCLEROSIS; BLOOD CLOTTING; BODY WEIGHT LOSS; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HEART FAILURE; HUMAN; IMMUNOMODULATION; INTESTINE MUCOSA; LIPID FINGERPRINTING; LUNG; MOUTH MUCOSA; OBESITY; PHYSICAL ACTIVITY; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; COMPLICATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS;

EID: 85065819406     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2020.102601     Document Type: Erratum

References (221)

1. Lee, K.S., Kronbichler, A., Eisenhut, M., Lee, K.H., Shin, J., Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians. Autoimmun Rev 17 (2018), 201–214.
2. England, B.R., Sayles, H., Michaud, K., Caplan, I., davis LA, Cannon GW, et al., Cause specific mortality in male US veterans with Rheumatoid Arthritis. Arthritis Care Res 68 (2016), 36–45.
3. Nakajima, A., Inoue, E., Tanaka, E., Singh, G., Sato, D., et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39 (2010), 360–367.
4. Sparks, J.A., Chang, S.C., Liao, K.P., Lu, B., Fine, A.R., Solomon, D.H., et al. Rheumatoid Arthritis and mortality among women during 36 years of prospective follow-up: results from the nurses' health study. Arthritis Care Res 68 (2016), 753–762.
5. Kisiel, B., Kruszewski, R., Juszkiewicz, A., Klos, K., Tlustochowicz, M., Thustochowicz, W., Prevalence of atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis. Pak J Med Sci 31 (2015), 1078–1083.
6. Ruscitti, P., Cipriani, P., Masedu, F., Romano, S., Berardicurti, O., Liakouli, V., et al. Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study. PLoS One, 12, 2017, e0170108.
7. Watson, D.J., Rhodes, T., Guess, H.A., All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK general Practice Database. J Rheumatol 30 (2003), 1196–1202.
8. Fischer, L.M., Schlienger, R.G., Matter, C., Jick, H., Meier, C.R., Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first time acute myocardial infarction. Am J Cardiol 93:2 (2004), 198–200.
9. Solomon, D.H., Karlson, E.W., Rimm, E.B., Cannuscio, C.C., Mandl, L.A., Manson, J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:9 (2003), 1303–1307.
10. Del, R.I., Williams, K., Stern, M.P., Freeman, G.L., Escalante, A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:12 (2001), 2737–2745.
11. Charles-Schoeman, C., Cardiovascular Disease and Rheumatoid Arthritis: an Update. Curr Rheumatol Rep 14:5 (2012), 455–462.
12. Maradit-Kremers, H., Nicola, P.J., Crowson, C.S., Ballman, K.V., Gabriel, S.E., Cardiovascular death in rheumatoid arthritis: a population based study. Arthritis Rheum 52:3 (2005), 722–732.
13. Wallberg-Johnsson, S., Johansson, H., Ohman, M.L., Rantapaa-Dahlqvist, S., Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26:12 (1999), 2562–2571.
14. Chung, C.P., Oeser, A., Raggi, P., Gebretsadik, T., Shintani, A.K., Sokka, T., et al. Increased coronary artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:10 (2005), 3045–3053.
15. Del, R.I., Freeman, G.L., Haas, R.W., O'Leary, D.H., Escalante, A., Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 52:11 (2005), 3413–3423.
16. Giles, J.T., Post, W.S., Blumenthal, R.S., Polak, J., Petri, M., Gelber, A.C., et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 63:11 (2011), 3216–3425 (Higher swollen joint counts and higher average C-reactive protein levels were associated with incident as well as progressive carotid plaque in a 158 patient RA cohort followed for 3 years).
17. Jagpal, A., Navarro-Millan, I., Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol, 2, 2018, 10.
18. Peters, M.J., van Halm, V.P., Voskuyl, A.E., Smulders, Y.M., Boers, M., Lems, W.F., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? a prospective study. Arthritis Rheum 6:1 (2009), 1571–1579.
19. Stamatelopoulos, K.S., Kitas, G.D., Papamichael, C.M., Chryssohoou, E., Kyrkou, K., Georgiopoulos, G., et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscl Thromb Vasc Biol 29:10 (2009), 1702–1708.
20. Karpouzas, G.A., Malpeso, J., Choi, T.Y., Li, D., Munoz, S., Budoff, M.J., Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 73:10 (2014), 1797–1804.
21. Van Doornum, S., Brand, C., King, B., Sundararajan, V., Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 54:7 (2006), 2061–2068.
22. Avina-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., Etminan, M., Esdaile, J.M., Lacaille, D., Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:12 (2008), 1690–1697.
23. Meune, C., Touze, E., Trinquart, L., Allanore, Y., Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxf) 48:10 (2009), 1309–1313.
24. Sparks, J.A., Chang, S.C., Liao, K.P., Lu, B., Fine, A.R., Solomon, D.H., et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow up: results from the Nurses' health study. Arthritis Care Res 68:6 (2016), 753–762.
25. Michaud, K., Berglind, N., Franzen, S., Frisell, T., Garwood, C., Greenberg, J.D., et al. Can rheumatoid arthritis registries provide contextual safety data for modern RA clinical trials? the case for mortality and cardiovascular disease. Ann Rheum Dis 75:10 (2016), 1797–1805.
26. Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Lopez-Diaz, M.J., Pineiro, A., Garcia-Porrua, C., Miranda-Filloy, J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57:11 (2007), 125–132.
27. Del Rincon, I., Battafarano, D.F., Restrepo, J.F., Erikson, J.M., Escalante, A., Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 66:2 (2014), 264–272.
28. Humphreys, J.H., Warner, A., Chipping, J., Marshall, T., Lunt, M., Symmons, D.P., et al. Mortality trends in patients with early rheumatoid arthritis over 20 years' results from the Norfolk arthritis register. Arthritis Care Res 66:9 (2014), 1296–1301.
29. Goodson, N.J., Wiles, N.J., Lunt, M., Barrett, E.M., Silman, A.J., Symmons, D.P., Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46:8 (2002), 2010–2019.
30. Lindhardsen, J., Ahlehoff, O., Gislason, G.H., Madsen, O.R., Olesen, J.B., Svendsen, J.H., et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: danish nationwide cohort study. BMJ, 344, 2012, e1257.
31. Lazzerini, P.E., Capecchi, P.I., Galeazzi, M., Laghi-Pasini, F., Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. Immunol Res 65 (2017), 262–275.
32. DIF, M., Paradiso, M., Ceccarelli, F., Scrivo, R., Spinelli, F.R., Iannuccelli, C., et al. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT disperson. J Rheumatol 39 (2012), 41–45.
33. Syngle, A., Verma, I., Krishan, P., Interleukin 6 blockade improves autonomic dysfunction in rheumatoid arthritis. Acta Rheumatol Port 40 (2015), 85–88.
34. Rantapaa-Dahlqvist, S., de Jong, B.A., Berglin, E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48 (2003), 2741–2749.
35. Nielen, M.M., van Schaardenburg, D., reesink HW, et al., Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50 (2004), 380–386.
36. Nielsen, S.F., Bojesen, S.E., Schnohr, P., Nordestgaard, B.G., Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ, 345, 2012, e5244.
37. Ercan, A., Cui, J., Chatterton, D.E., et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 62 (2010), 2239–2248.
38. Suwannalai, P., van de Stadt, L.A., Radner, H., et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 64 (2012), 1323–1328.
39. Brink, M., Hansson, M., Mathsson, L., et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 65 (2013), 899–910.
40. Sokolove, J., Bromberg, R., Deane, K.D., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One, 7, 2012, e35296.
41. Hughes-Austin, J.M., Deane, K.D., Derber, L.A., et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis 72 (2013), 901–907.
42. Kokkonen, H., Soderstrom, I., Rocklow, J., Hallmans, G., Lejon, K., Rantapaa, Dahlqvist S., Up regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 62 (2010), 383–391.
43. Deane, K.D., O‘Donnell CI, Hueber W, et al., The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 62 (2010), 3161–3172.
44. Masson-Bessiere, C., Sebbag, M., Durieux, J.J., et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119 (2000), 544–552.
45. Snir, O., Widhe, M., Hermansson, M., et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 62 (2010), 44–52.
46. Van de Sande, M.G., de Hair, M.J., van der Leij, C., et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 70 (2011), 772–777.
47. Krabben, A., Stomp, W., van der Heijde, D.M., et al. MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Ann Rheum Dis 72:9 (2013), 1540–1544.
48. Gent, Y.Y., Voskuyl, A.E., Kloet, R.W., et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum 64 (2012), 62–66.
49. Van de Stadt, L.A., Bos, W.H., Mearsinge Reynders, M., et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther, 12(R 98), 2010.
50. Svard, A., Kastbom, A., Soderlin, M.K., Reckner-Olsson, A., Skogh, T., A comparison between IgG and IgA class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 38 (2011), 1265–1272.
51. Kokkonen, H., Mullazehi, M., Berglin, E., et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther, 13(1), 2011, R13.
52. Barra, L., Scinocca, M., Saunders, S., et al. Anti-citrullinated protein antibodies (ACPA) in unaffected first degree relatives of rheumatoid arthritis patients. Arthritis Rheum 65:6 (2013), 1439–1447.
53. Carter, J.D., Hudson, A.P., Reactive arthritis: clinical aspects and medical management. Rhematic Dis Clin North Am 35 (2009), 21–44.
54. Dissick, A., Redman, R.S., Jones, M., et al. Association of periodontitis with rheumatoid arthritis: a pilot study. J Periodontol 81 (2010), 223–230.
55. Nesse, W., Dijkstra, P.U., Abbas, F., et al. Increased prevalence of cardiovascular and autoimmune diseases in periodontitis patients: a cross-sectional study. J Periodontol 81 (2010), 1622–1628.
56. Smit, M.D., Westra, J., Vissink, A., Doornbos-van der Meer B, Brouwer E, van Winkelhoff AJ. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther, 14L(R222), 2012.
57. Havemose-Poulsen, A., Westergaard, J., Stolze, K., et al. Periodontal and hematological characteristics associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. J Periodontol 77 (2006), 280–288.
58. Hendler, A., Mulli, T.K., Hughes, G.J., et al. Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. J Dent Res 89 (2010), 1389–1394.
59. Wegner, N., Wait, R., Sroka, A., et al. Peptidylarginine deaminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 62 (2010), 2662–2672.
60. Mikulus, T.R., Thiele, G.M., Deane, K.D., et al. Porphyromonas gingivalis and disease related autoantibodies in individuals at increased risk for future rheumatoid arthritis. Arthritis Rheum, 64(11), 2012, 10.1002/art.34595.
61. Harvey, G.P., Fitzsimmons, T.R., Dhamarpatni, A.A., Marchant, C., Haynes, D.R., Bartold, P.M., Expression of peptidylarginine deaminase-2 and -4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva. J Periodontal Res 48 (2013), 252–261.
62. Blum, A., Front, E., Peleg, A., Periodontal care may improve systemic inflammation. Clin Invest Med 30:3 (2007), 114–117.
63. Oliver, J.E., Silman, A.J., Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 35 (2006), 169–174.
64. Klareskog, L., Stolt, P., Lundberg, K., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR restricted immune reactions to auto antigens modified by citrullination. Arthritis Rheum 54 (2006), 38–46.
65. Han, Y.W., Wang, X., Mobile microbiome: oral bacteria in extra-oral infections and inflammation. J Dent Res 92 (2013), 485–491.
66. Somma, F., Castagnola, R., Bollino, D., Marigo, I., Oral inflammatory process and general health. Part 1: the focal infection and the oral inflammatory lesion. Eur Rev Med Pharmacol Sci 14 (2010), 1085–1095.
67. Ferretti, J.J., Shea, C., Humphrey, M.W., Cross reactivity of Streptoccocus mutans antigens and human heart tissue. Infect Immun 30 (1980), 69–73.
68. Stolt, P., Kallberg, H., Lundberg, I., Sjogren, B., Klreskog, L., Alfredsson, L., Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 64 (2005), 582–586.
69. Demoruelle, M.K., Weisman, M.H., Simonian, P.L., et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?. Arthritis Rheum 64 (2012), 1756–1761.
70. Fischer, A., Solomon, J.J., du Bois, R.M., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106 (2012), 1040–1047.
71. Willis, V.C., Demoruelle, M.K., Derber, L.A., et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at-risk for future clinically apparent disease. Arthritis Rheum 65:10 (2013), 2545–2554.
72. Dimmitt, R.A., Staley, E.M., Chuang, G., Tanner, S.M., Soltau, T.D., Lorenz, R.G., Role of postnatal acquisition of the intestinal microbiome in the early development of immune function. J Perdiatr Gastroenterol Nutr 51 (2010), 262–273.
73. Stebbings, S.M., Taylor, C., Tannock, G.W., Baird, M.A., Highton, J., The immune response to autologous bacteroides in ankylosing spondylitis is characterized by reduced interleukin 10 production. J Rheumatol 36 (2009), 797–800.
74. Abdollahi-Roodsaz, S., Joosten, L.A., Koenders, M.I., et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 118 (2008), 205–216.
75. Wu, H.J., Ivanov, I., Darce, J., et al. Gut residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32 (2010), 815–827.
76. Horai, R., Saijo, S., Tanioka, H., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191 (2000), 313–320.
77. Liu, X., Zou, Q., Zeng, B., Fang, Y., Wei, H., Analysis of fecal lactobacillus community structure in patients with early rheumatoid arthritis. Curr Microbiol 67 (2013), 170–176.
78. Vaahtovuo, J., Munukka, E., Korkeamaki, M., Luukkainen, R., Toivanen, P., Fecal microbiota in early rheumatoid arthritis. J Rheumatol 35 (2008), 1500–1505.
79. Newkirk, M.M., Goldbach-Mansky, R., Senior, B.W., Klippel, J., Schumacher, H.R. Jr., El-Gabalawy, H.S., Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor positive rheumatoid arthritis. Rheumatol (Oxf) 44 (2005), 1433–1441.
80. Rashid, T., Ebringer, A., Rheumatoid arthritis is linked to Proteus – the evidence. Clin Rheumatol 26 (2007), 1036–1043.
81. Roman, M.J., Devereux, R.B., Schwartz, J.E., Lockshin, M.D., Paget, S.A., Davis, A., et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 46:1 (2005), 194–199.
82. Klocke, R., Cockcroft, J.R., Taylor, G.J., Hall, I.R., Blake, D.R., Arterial stiffness and central blood pressure. Ann Rheum Dis 62:5 (2003), 414–418.
83. Solak, Y., Afsar, B., Vaziri, N.D., Aslan, G., Yalcin, C.E., Covic, A., et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res 39:8 (2016), 567–573.
84. Van Lenten, B.J., Hama, S.Y., de Beer, F.C., Stafforini, D.M., McIntyre, T.M., Prescott, S.M., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell co-cultures. J Clin Invest 96:6 (1995), 2758–2767.
85. Van Lentin, B.J., Wagner, A.C., Nayak, D.P., Hama, S., Navab, M., Fogelman, A.M., High density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103:18 (2001), 2283–2288.
86. Tektonidou, M.G., Kravvariti, E., Konstantonis, G., Tentolouris, N., Sfikakis, P.P., Protogerou, A., Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmun Rev 16 (2017), 308–312.
87. Wu, G.C., Liu, H.R., Leng, R.X., Li, X.P., Li, X.M., Pan, H.F., et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev 15 (2016), 22–37.
88. Ambrosino, P., Lupoli, R., Minno, A., Tasso, M., Peluso, R., Di Minno, M.N., Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromn Haemost 113 (2015), 916–930.
89. Pinegin, B., Vorobjeva, N., Pinegin, V., Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev 14 (2015), 633–640.
90. Lee, K.H., Kronbichler, A., Park, D.D., Park, Y., Moon, H., Kim, H., et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a vpmprehensive review. Autoimmun Rev 16 (2017), 1160–1173.
91. Robert, M., Miossec, P., Effects of interleukin 17 on the cardiovascular system. Autoimmun Rev 16 (2017), 984–991.
92. Striz, I., Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations. Clin Sci 131 (2017), 2241–2256.
93. Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
94. Junge, G., Mason, J., Feist, E., Adult onset Still's disease – the evidence that anti-interleukin 1 treatment is effective and well tolerated. Semin Arthritis Rheum 47 (2017), 295–302.
95. Hourier, C., Seyed, J.S.M., Thomi, R., Schlaphach, C., Borradori, I., Yawalkar, N., et al. canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases. JAMA Dermatol 153 (2017), 1195–1197.
96. Ozdogan, H., Ugurlu, S., Canakinumab for the treatment of familial mediteranean fever. Expert Rev Clin Immunol 13 (2017), 393–404.
97. Ummarino, D., Autoinflammation: canakinumab effective in HIDS treatment. Nat Rev Rheumatol, 13, 2017, 388.
98. Fabiani, C., Vitale, A., Wmmi, G., Lopalco, G., Vannozzi, I., Guerriero, S., et al. Interleukin 1 inhibition with anakinra and canakinumab in Bechcet's diseases-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36 (2017), 191–197.
99. Navab, M., Berliner, J.A., Subbanagounder, G., Hama, S., Lusis, A.J., Castellani, L.W., et al. HDL and the inflammatory response induced by LDL derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:4 (2001), 481–488.
100. McGillicuddy, F.C., de la Llera, M.M., Hinkle, C.C., Joshi, M.R., Chiquoine, E.H., Billheimer, J.T., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 119:8 (2009), 1135–1145.
101. Charles-Schoeman, C., Watanabe, J., Lee, Y.Y., Furst, D.E., Amjadi, S., Elashoff, D., et al. Abnormal function of high density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60:10 (2009), 2870–2879.
102. McMahon, M., Grossman, J., Skaggs, B., Fitzgerald, J., Sahakian, L., Ragavendra, N., et al. Dysfunctional pro-inflammatory high-density lipoprotein confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:8 (2009), 2428–2437.
103. Oram, J.F., Yokoyama, S., Apo lipoprotein mediated removal of cellular cholesterol and phospholipids. J Lipid Res 37:12 (1996), 2473–2491.
104. Navab, M., Hama, S.Y., Anantharamaiah, G.M., Hassan, K., Hough, G.P., Watson, A.D., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41:9 (2000), 1495–1508.
105. Navab, M., Hama, S.Y., Cooke, C.J., Anantharamaiah, G.M., Chaddha, M., Jin, L., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41:9 (2000), 1481–1494.
106. Navab, M., Hama-Levy, S., Van Lenten, B.J., Fonarow, G.C., Cardinez, C.J., Castellani, L.W., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxanase ratio. J Clin Invest 99:8 (1997), 2005–2019.
107. Watson, A.D., Navab, M., Hama, S.Y., Sevanian, A., Prescott, S.M., Stafforini, D.M., et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95:2 (1995), 774–782.
108. Mackness, M.I., Arrol, S., Durrington, P.N., Paraoxanase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 286:1-2 (1991), 152–154.
109. Khera, A.V., Cuchel, M., De, I.L.-M., Rodrigues, A., Burke, M.F., Jafri, K., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:2 (2011), 127–135.
110. Charles-Schoeman, C., Lee, Y.Y., Grijalva, V., Amjadi, S., Fitzgerald, J., Ranganath, V.K., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71:7 (2012), 1157–1162.
111. Watanabe, J., Charles-Schoeman, C., Miao, Y., Elashoff, D., Lee, Y.Y., Katselis, G., et al. Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum 64:6 (2012), 1828–1837.
112. Nadkarni, A., You, M., Resuehr, H., Curtis, J.R., The risk for cardiovascular events associated with hyperlipidemia among patients with and without rheumatoid arthritis. J Arthritis, 4(4), 2015, 178.
113. Van Halm, V.P., Nielen, M.M., Nurmohamed, M.T., van Schaardenburg, D., Reesink, H.W., Voskuyl, A.E., et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 66:2 (2007), 184–188.
114. Boffa, M.B., Koschinsky, M.L., Lipoprotein (a): truly a direct pro-thrombotic factor in cardiovascular disease?. J Lipid Res 57:5 (2016), 745–757.
115. Zhang, C., Li, X., Niu, D., Zi, R., Wang, C., Han, A., et al. Increased serum levels of β2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients with rheumatoid arthritis. Clin Chim Acta 412:15-16 (2011), 1332–1336.
116. Choi, H.K., Seeger, J.D., Lipid profiles among US elderly with untreated rheumatoid arthritis-the third National Health and nutrition examination survey. J Rheumatol 32:12 (2005), 2311–2316.
117. Myasoedova, E., Crowson, C.S., Kremers, H.M., Roger, V.L., Fitz-Gibbon, P.D., Thermeau, T.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70:3 (2011), 482–487.
118. Semb, A.G., Kvien, T.K., Aastveit, A.H., Junger, I., Pedersen, T.R., Walldius, G., et al. Lipids, myocardial infarction and ischemic stroke in patients witrh rheumatoid arthritis in the apo-lipoprotein related mortality Risk (AMORIS) study. Ann Rheum Dis 69:11 (2010), 1996–2001.
119. Toms, T.E., Panoulas, V.F., Douglas, K.M., Nightingale, P., Smith, J.P., Griffiths, H., et al. Are lipid ratios susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?. Angiology 62:2 (2011), 167–175.
120. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr., Kastelein, J.J., et al. Reduction in C reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:9670 (2009), 1175–1182.
121. Zhang, J., Chen, L., Delzell, E., Munter, P., Hillegass, W.B., Safford, M.M., et al. The association between inflammatory markers, serum lipids, and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 73:7 (2014), 1301–1308.
122. Choy, E., Sattar, N., Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:4 (2009), 460–469.
123. Liao, K.P., Diogo, D., Cui, J., Cai, T., Okada, Y., Gainer, V.S., et al. Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls. Ann Rheum Dis 73:6 (2014), 1170–1175.
124. Robertson, J., Peters, M.J., Mcinnes, I.B., Sattar, N., Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:9 (2013), 513–523.
125. Emerey, P., Keystone, E., Tony, H.P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., et al. IL-6 receptor inhibition with tocillizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 67:11 (2008), 1516–1623.
126. Genoverse, M.C., McKay, J.D., Nasonov, E.L., Mysler, E.F., da Silva, N.A., Alecock, E., et al. Interleukin 6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease modifying antirheumatic drugs: the tocilizumab in combination with traditional disease modifying anti-rheumatic drug therapy study. Arthritis Rheum 58:10 (2008), 2968–2980.
127. Innala, L., Moller, B., Ljung, L., Magnusson, S., Smedby, T., Sodergren, A., et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther, 13(4), 2011, R131.
128. Naranjo, A., Sokka, T., Descalzo, M.A., Calco-Alen, J., Horslev-Petersen, K., Luukkainen, R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther, 10(2), 2008, R30.
129. Blum, A., Shamburek, R., The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203 (2009), 325–330.
130. Li, G., Zhao, J., Li, B., Zhang, X., Ma, J., Ma, X., et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev 17 (2018), 215–225.
131. Chung, C.P., Oeser, A., Solus, J.F., Avalos, I., Gebretsadik, T., Shintani, A., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196:2 (2008), 756–763.
132. Han, C., Robinson, D.W., Hackett, M.V., Paramore, L.C., Framan, K.H., Bala, M.V., Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:11 (2006), 2167–2172.
133. Adawi, M., Watad, A., Bragazzi, N.L., Amital, H., Saaida, G., Sirchan, R., et al. Endothelial function in rheumatoid arthritis. QJM, 2018, 243–247.
134. Adawi, M., Pastukh, N., Saaida, G., Sirchan, R., Watad, A., Blum, A., Inhibition of endothelial progenitor cells may explain the high cardiovascular event rate in patients with rheumatoid arthritis. QJM, 2018, 525–529.
135. Hill, J.M., Zalos, G., Halcox, J.P.J., Schenke, W.H., Waclawiw, M.A., Quyyumi, A.A., et al. Circulating endothelial progenitor cells, vascular fucntion, and cardiovascular risk. NEJM 348 (2003), 593–600.
136. Pirro, M., Schillaci, G., Menecali, C., et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens 25:10 (2007), 2093–2099.
137. Umemura, T., Soga, J., Hidaka, T., et al. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens 21:11 (2008), 1203–1209.
138. Choi, J.H., Kim, K.L., Huh, W., et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. ATVB 24:7 (2004), 1246–1252.
139. De Groot, K., Bahlmann, F.H., Sowa, J., et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 66:2 (2004), 641–646.
140. Lorenzen, J., David, S., Bahlmann, F.H., et al. Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease: a prospective follow-up study. PLoS One, 5(7), 2010, e11477.
141. Werner, N., Kosiol, S., Schiegel, T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. NEJM 353:10 (2005), 999–1007.
142. Ghani, U., Shuaib, A., Salam, A., et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 36:1 (2005), 151–153.
143. Blum, A., Pastukh, N., Sirchan, R., Blum, N., Chernikoff, L., Vaispapir, V., Inhibition of Endothelial Progenitor Cells in the first 24 hours of an Acute Ischemic Cerebrovascular Event. IMAJ 21 (2019), 71–76.
144. Shintani, S., Murohara, T., Ikeda, H., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103:23 (2001), 2776–2779.
145. George, J., Goldstein, E., Abashidze, S., et al. Circulating endothelial cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 25:12 (2004), 1003–1008.
146. Guven, H., Shepherd, R.M., Bach, R.G., Capoccia, B.J., Link, D.C., The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. JACC 48:8 (2006), 1579–1587.
147. Schmidt Lucke, C., Rossing, L., Fichtlscherer, S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111:22 (2005), 2981–2987.
148. Xiao, Q., Kiechl, S., Patel, S., et al. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis – results from a large population based study. Plos One, 2(10), 2007, e975.
149. Fadini, G.P., Sartore, S., Albiero, M., et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. ATVB 26:9 (2006), 2140–2146.
150. Fadini, G.P., Sartore, S., Bacsso, I., et al. Endothelial progenitor cells and the diabetic paradox. Diabetes Care 29:3 (2006), 714–716.
151. BlumA, Socea D., Pastukh, N., Jabaly, H., Colony Forming Unites-Endothelial Progenitor Cells (CFU-EPCs): a Surrogate Marker for Diabetic Retinopathy and High Cardiovascular Mortality Rate. Int J Pharma Res Rev 5:5 (2016), 57–62.
152. Makino, H., Okada, S., Nagumo, A., et al. Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabet Med 26:2 (2009), 171–173.
153. Fadini, G.P., Maruyama, S., Ozaki, T., et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One, 5(7), 2010, e11488.
154. Michowitz, Y., Goldstein, E., Wexler, D., Sheps, D., Keren, G., George, J., Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart 93:9 (2007), 1046–1050.
155. Erbs, S., Hollriegel, R., Linke, A., et al. exercise training in patients with advanced chronic heart failure (NHYA IIIb) promotes restoration of peripheral vasomotor function, induction of endogenous regeneration, and improvement of left ventricular function. Circ Heart Fail 3:4 (2010), 486–494.
156. Wolfe, F., Mitchell, D.M., Sibley, J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 37:4 (1994), 481–494.
157. Del Rincon, I.D., Williams, K., Stern, M.P., Freeman, G.L., Escalante, A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:12 (2001), 2737–2745.
158. Sarzi-Puttini, P., Atzeni, F., gerli R, et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmune. Rev. 9:12 (2010), 849–852.
159. Szekanecz, Z., Koch, A.E., Vascular involvement in rheumatic diseases: vascular rheumatology. Arthritis Res Ther, 10(5), 2008, 224.
160. Urowitz, M.B., Bookman, A.A., Koehler, B.E., Gordon, D.A., Smythe, H.A., Ogryzlo, M.A., The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:2 (1976), 221–225.
161. Rubin, L.A., Urowitz, M.B., Gladman, D.D., Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 55:216 (1985), 87–98.
162. Grisar, J., Aletaha, D., Steiner, C.W., et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111:2 (2005), 204–211.
163. Grisar, J., Aletaha, D., Steiner, C.W., et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumor necrosis factor and glucocorticoid therapy. Ann Rheum Dis 66:10 (2007), 1284–1288.
164. Herbrig, K., Haensel, S., Oelschlaegel, U., Pistrosch, F., Foerster, S., Passauer, J., Endothelial dysfunction in patients with rheumatoid arthritis is asociated with a reduced number and impaired functions of endothelial progenitor cells. Ann Rheum Dis 65:2 (2006), 157–163.
165. Paleolog, E., It's all in the blood: circulating endothelial progenitor cells link synovial vascularity with cardiovascular mortality in rheumatoid arthritis?. Arthritis Res Ther 7:6 (2005), 270–272.
166. Moonen, J.R., de Leeuw, K., van Seijen, X.J., et al. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther, 9(4), 2007, R84.
167. Westerweel, P.E., Luijten, R.K., Hoefer, I.E., Koomans, H.A., Derksen, R.H., Verhaar, M.C., Hematopoietic and endothelial progenitor cells are deficient in quiscent systemic lupus erythematosus. Ann Rheum Dis 66:7 (2007), 865–870.
168. Denny, M.F., Thacker, S., Mehta, H., et al. Interferon α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110:8 (2007), 2907–2915.
169. Lee, P.Y., Li, Y., Richards, H.B., et al. Type 1 interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56:11 (2007), 3759–3769.
170. Verma, S., Kuliszewski, M.A., Li, S.H., et al. C reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C reactive protein and cardiovascular disease. Circulation 109:17 (2004), 2058–2067.
171. Ciulla, M.M., Giorgetti, A., Silvestris, I., et al. Endothelial colony forming capacity is related to C reactive protein levels in healthy subjects. Curr Neurovasc Res 3:2 (2006), 99–106.
172. Fujii, H., Li, S.H., Szmitko, P.E., Fedak, P.W., Verma, S., C reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. ATVB 26:11 (2006), 2476–2482.
173. Gabay, C., Interleukin 6 and chronic inflammation. Arthritis Res Ther, 8(Suppl. 2), 2006, S3.
174. Patel, A.M., Moreland, L.W., Interleukin 6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 4 (2010), 263–278.
175. Fan, Y., Ye, J., Shen, F., et al. Interleukin 6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Metab 28:1 (2008), 90–98.
176. Bonsignore, M.R., Morici, G., Riccioni, R., et al. Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. J Appl Physiol 109:1 (2010), 60–67.
177. Ablin, J.N., Boguslavski, V., Aloush, V., et al. effect of anti-TNF treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 79:25 (2006), 2364–2369.
178. Sibal, L., Aldibbiat, A., Agarwal, S.C., et al. Circulating endothelial progenitor cells, endothelial function, carotid intima thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without microvascular disease or micro albuminuria. Diabetologia 52:8 (2009), 1464–1473.
179. Chen, T.G., Zhong, Z.Y., Sun, G.F., Zhou, Y.X., Zhao, Y., Effects of tumor necrosis factor a on activity and nitric oxide synthase of endothelial progenitor cells from peripheral blood. Cell Prolif 44:4 (2011), 352–359.
180. Henrich, D., Seebach, C., Wilhelm, K., Marzi, I., high dosage of simvastatin reduces TNF induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1 in vitro. J Surg Res 142:1 (2007), 13–19.
181. Hamed, S., Brenner, B., Roguin, A., Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type 2. Cardiovasc Res 91 (2011), 9–15.
182. Aicher, A., Heeschen, C., Mildner-Rihm, C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9:11 (2003), 1370–1376.
183. Raemdonck, K.V., Umar, S., Szekanecz, Z., Zomorrodi, R.K., Shahrara, S., Impact of obesity on autoimmune arthritis and its cardiovascular complications. Autoimmun Rev 17 (2018), 821–835.
184. Philippou, E., Nikiphorou, E., Are we what we eat? nutrition and its role in the onset of rheumatoid arthritis. Autoimmun Rev 17 (2018), 1074–1077.
185. Bhole, V.M., Choi, H.K., Burns, L.C., Vera, C., Lacaille, D.V., Gladman, D.D., et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology 51 (2012), 552–556.
186. Stavopoulos-Kalinoglou, A., Metsios, G.S., Koutedakis, Y., Kitas, G.D., Obesity in rheumatoid arthritis. Rheumatology 50 (2011), 450–462.
187. Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., et al. CCR2 modulates inflammatory and metabolic effects of high fat feeding. J Clin Invest 116 (2006), 115–124.
188. Endo, Y., Yokore, K., Nakayama, T., The obesity related pathology and Th17 cells. Cell Mol Life Sci 74 (2017), 1231–1245.
189. Lee, Y., Awasthu, A., Yosef, N., Quitanna, F.J., Xiao, S., Peters, A., et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13 (2012), 991–999.
190. Van de Wiele, T., Van Praet, J.T., Marzorati, M., Drennan, M.B., Elewaut, D., How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol 12 (2016), 398–411.
191. Sharif, K., Watad, A., Bragazzi, N.L., Lichtbroun, M., Amital, H., Shoenfeld, Y., Physical activity and autoimmune diseases: get moving and manage the disease. Autoimmun Rev 17 (2018), 53–72.
192. Xiang, L., Rehm, K.E., Marshall, G.D. Jr., Effects of strenuous exercise on Th1/Th2 gene expression from human peripheral blood mononuclear cells of marathon participants. Mol Immunol 60:2 (2014), 129–134.
193. Wilson, L.D., Zaldivar, F.P., Schwindt, C.D., Wnag-Rodriguez, J., Cooper, D.M., Circulating T regulatory cells, exercise and the elite adolescent swimmer. Pediatr Exerc Sci 21:3 (2009), 305–317.
194. Smith, J., Mckenzie, S., Telford, R., Weidemann, M., Why does moderate exercise enhance, but intense training depress, immunity. Behav Immun, 1992, 155–168.
195. Di Giuseppe, D., Bottai, M., Akling, J., Wolk, A., Physical activity and risk of rheumatoid arthritis in women: a population-based prospective study. Arthritis Res Ther, 17(1), 2015.
196. Metsios, G.S., Stavropoulos-Kalinoglou, A., Sandoo, A., van Zanten, J.J., Toms, T.E., John, H., et al. Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Open Cardiovasc Med J 4 (2010), 89–96.
197. Van Hoogmoed, D., Fransen, J., Bleijenberg, G., van Riel, P., Physical and psychological correlates of severe fatigue in rheumatoid arthritis. Rheumatology 49:7 (2010), 1294–1302.
198. Bili, A., Tang, X., Pranesh, S., et al. Tumor necrosis factor a inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res 66 (2014), 355–366.
199. Desai, R.J., Rao, J.K., hansen RA, et al., Tumor necrosis factor a inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 41 (2014), 2129–2136.
200. Roubille, C., Richer, V., Stamino, T., et al. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74 (2015), 480–489.
201. Dixon, W.G., Symmons, D.P., What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? a review of the role of TNF in cardiovascular pathophysiology. Ann Rheum Dis 66 (2007), 1132–1136.
202. Hyrich, K.L., Watson, K.D., Isenberg, D.A., et al. The British Society for Rheumatology Biologics register: 6 years on. Rheumatology 47 (2008), 1441–1443.
203. Ljung, L., Askling, J., Rantapaa-Dahlqvist, S., et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumor necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther, 16(3), 2014, R127.
204. Daiien, C.I., Duny, Y., Bametche, T., et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a system review with meta-analysis. Ann Rheum Dis 71 (2012), 862–868.
205. Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., et al. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193 (2010), 153–159.
206. Low, A.S.L., Symmons, D.P.M., Lunt, M., et al. relationship between exposure to tumor necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 76 (2017), 654–660.
207. Lim, D.T., Cannella, A.C., Michaud, K.D., Mikuls, T.R., Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. Curr Rheumatol Rep 16 (2014), 459–469.
208. Peters, M.J., van der Horst-Bruinsma, I.E., Dijkmans, B.A., Nurmohamed, M.T., Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34 (2004), 585–592.
209. Bujak, M., Frangogiannis, N.G., The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 57:3 (2009), 165–176.
210. Danesh, J., Kaptoge, S., Mann, A.G., et al. Long term interleukin 6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med, 5(4), 2008, e78.
211. Su, D., Li, Z., Li, X., et al. Association between serum interleukin 6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm, 726178, 2013, 10.1155/2013/726178.
212. Ikonomidis, I., Lekakis, J.P., Nikolaou, M., et al. Inhibition of interleukin 1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117:20 (2008), 2662–2669.
213. Ikonomidis, I., Rzortzis, S., Andreadou, I., et al. Increased benefit of interleukin 1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid rheumatoid arthritis. Circ Cardiovasc Imaging 7:4 (2014), 619–628.
214. Abbate, A., Salloum, F.N., Vecile, E., et al. Anakinra, a recombinant human interleukin 1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117:20 (2008), 2670–2683.
215. Van Tassell, B.W., Arena, R., Biondi-Zoccai, G., et al. Effects of interleukin 1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction. Am J Cardiol 113:2 (2014), 321–327.
216. Protogerou, A.D., Zampeli, E., Fragiadaki, K., et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin 6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219:2 (2011), 734–736.
217. McInnes, I.B., Thompson, L., Giles, J.T., et al. Effect of interleukin 6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: measure, a randomized, placebo-controlled study. Ann Rheum Dis 74:4 (2015), 694–702.
218. Gonzalez-Juanatey, C., Llorca, J., Vazquez-Rodriguez, T.R., et al. Short term improvement of endothelial function in rituximab treated rheumatoid arthritis patient's refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:12 (2008), 1821–1824.
219. Kerekes, G., Soltesz, P., Der, H., et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 28:6 (2009), 705–710.
220. Jin, Y., Kang, E.H., Brill, G., et al. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol 45:9 (2018), 1240–1248.
221. Kaur, K., Kalra, S., Kaushal, S., Systemic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther 36:7 (2014), 1074–1086.